Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.78 |
| ▸ | MAOB | P27338 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459647 | 0.89 | MAOA (0.75) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL14339477 | 0.89 | MAOA (0.75) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL14480152 | 0.89 | MAOA (0.78) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL22689293 | 0.88 | MAOA (0.69) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL22689292 | 0.88 | MAOA (0.69) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL24169742 | 0.87 | MAOA (1.00) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL18410322 | 0.87 | MAOA (1.00) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL5234003 | 0.87 | MAOA (0.82) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL5315180 | 0.87 | MAOA (0.82) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL11983302 | 0.87 | MAOA (0.73) | MAOAMAOBKCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | MAOA 743/4885MAOB 739/4885KCNH2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.